PAX5 and cancer: Studies have shown that PAX5 is expressed in Hodgkin and B-cell non-Hodgkin lymphomas, precursor B-cell lymphoblastic neoplasms, medulloblastoma, Merkel cell carcinoma, differentiated neuroendocrine carcinoma of the digestive system, small cell lung carcinoma, and rhabdomyosarcoma, suggesting that it might be a biomarker for the diagnosis or prognosis of those cancers [5,9,10,11,12,13].